Increased cardiovascular risk with second-generation antipsychotic agent switches

Journal of the American Pharmacists Association

Volumn 46, Issue 4, 2006, Pages 491-501

  Ried, L Douglas ^a,b   Renner, Bernard T ^c   McConkey, Joel R ^a   Bengtson, Michael A ^b,d   Lopez, Larry M ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Target Pharmacy   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic agents; Cardiovascular disease; Cardiovascular risk factors; Diabetes mellitus; Metabolic syndrome; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; LIPID;

BIOEQUIVALENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG CHOICE; DRUG SUBSTITUTION; HUMAN; MEDLINE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; TREATMENT OUTCOME; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; DRUG EFFECT; RISK; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; LIPIDS; RISK; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 33748533178     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434506778073574     Document Type: Article

References (55)

1. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60(suppl I):4-6; discussion 28-30.
2. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
3. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64:701-23.
4. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry. 2001;62(suppl 23):5-12.
5. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70:1-17.
6. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004;71:195-212.
7. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4-18; quiz 9-20.
8. Brown S, Inskip H, Barrclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212-7.
9. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
10. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64:575-9.
11. Kurzthaler I, Fleischhacker W. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62(suppl 7):32-7.
12. Tardieu S, Micallef J, Gentile S, Blin O. Weight gain profiles of new antipsychotics: public health consequences. Obes Rev. 2003;4:129-38.
13. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(suppl 1):S7-S14.
14. Ghaeli P, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy. 1999;19:1099-101.
15. McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry. 2001;62(suppl 23):23-9.
16. Baptista T. Mechanisms of weight gain induced by antipsychotic drugs. J Clin Psychiatry. 2002;63:245-6.
17. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002;35:205-19.
18. Pfizer Inc. Coronary Heart Disease (version 8) [computer software]. New York: Clinical Applications (Pfizer Inc.); 2004.
19. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-96.
20. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358-63.
21. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
22. Huang Z, Reddy A. Weight change, ideal weight and hypertension. Curr Opin Nephrol Hypertens. 1999;8:343-6.
23. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8:270-8.
24. Dyer AR, Elliott P. The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Co-operative Research Group. J Hum Hypertens. 1989;3:299-308.
25. Sharma S, Kortas C. Hypertension Emedicine Topic 1106. Accessed at www.emedicine.com/med/topic1106.htm, June 2, 2005.
26. Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY. The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs. J Clin Psychopharmacol. 2004;24:452-4.
27. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856-65.
28. Bouchard RH, Demers M, Simoneau I, et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharm. 2001;21:110-1.
29. Baymiller SP, Ball P, McMahon RP, Buchanon RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res. 2003;59:49-57.
30. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and RSP-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-33.
31. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 160:290-6.
32. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60:767-70.
33. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;(62 suppl 23):30-8.
34. Seroquel product labeling. Wilmington, Del.: AstraZeneca Pharmaceuticals; 2001.
35. Sacchetti E, Turrina C, Parrinello G, et al. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, risperidone, or quetiapine exposure. Int Clin Psychopharmacol. 2005;20:33-7.
36. Lambert T, Chapman L; Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus report. Med J Aust. 2004;181:544-8; author reply 310.
37. Henderson D, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19-28.
38. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62:92-100.
39. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161:1709-11.
40. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337-45.
41. Lambert BL, Chou CH, Chang KY, et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf. 2005;14:417-25.
42. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-6.
43. Citrome L, Jaffe A, Levine J, et al. relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv. 2004;55:1006-13.
44. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother. 2000;34:200-7.
45. Ganguli R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm. 2002;59(22 suppl 8):S22-S26.
46. Gupta S, Masand PS, Virk S, et al. Weight decline in patients switching from risperidone to quetiapine. Schizophr Res. 2004;70:57-62.
47. Ried LD, Renner BT, Bengtson M, et al. Weight change after an atypical antipsychotic switch. Ann Pharmacother. 2003;37:1381-6.
48. Thomas CJ. The effects of switching antipsychotics on lipids: a retrospective chart review. Seventh Annual Meeting, Annual Meeting of the College of Psychiatric and Neurologic Pharmacists. Chicago, Ill; April 23, 2004.
49. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595-600.
50. Jones A, Rak IW, Raniwalla J, et al. Weight changes in patients treated with quetiapine. Paper presented at: 153rd Annual Meeting of the American Psychiatric Association; May 13-18, 2000; Chicago, Ill.
51. Brecher M, Rak IW, Melvin K, Jones AM. The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract. 2000;4:287-91.
52. Henderson DC, Daley TB, Kunkel L, et al. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry. 2004;65:686-9.
53. Lieberman JA, Stroup TS, McEnvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23.
54. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
55. Grundy SM, Cleeman JI, Merz NB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel II Guidelines. Circulation. 2004;110:227-39.